We’ll send you a myFT Daily Digest email rounding up the latest Barr Pharms news every morning. Barr Pharmaceuticals, the US drugs group, on Wednesday emerged as the winner in the bidding war for ...

We’ll send you a myFT Daily Digest email rounding up the latest Croatia news every morning. Actavis, the Icelandic-based generic drugs company, on Thursday intensified the bidding war for Pliva of ...

On April 28, the US Food and Drug Administration's Center for Drug Evaluation and Research (Rockville, MD) issued a Warning Letter to Pliva Hrvatska d.o.o., a subsidiary of Pliva d.d. (Zagreb, Croatia ...

UK drug giant GlaxoSmithKline this morning said it is to buy the research arm of Croatia’s Pliva for up to $50 million in cash. UK drug giant GlaxoSmithKline this morning said it is to buy the ...

Pliva’s supervisory board issued a statement this morning lending its wholehearted support to the improved $2.5 billion offer for the business tendered by Iceland-headquartered generics group Actavis.

Pliva?s new Oral Solid Forms Facility will increase Pliva's production capacities for tablets and capsules. Pliva's new oral solid forms facility at its production site in Zagreb will increase Pliva's ...

Actavis made an unsolicited $1.6 billion bid for Pliva in March, and later increased the offer to $1.9 billion; Pliva rejected both offers as undervaluing its business. The real battle began late last ...

Excerpt from our Wall Street Breakfast, a one-page summary of this morning's key market-moving and stock-moving stories: Barr Buys Over 70% of Pliva Shares [Business Week] Summary: Barr ...

Pliva, a Zagreb, Croatia-based drug firm, expects to complete its exit from the proprietary drug business with an agreement to sell an R&D unit to GlaxoSmithKline. GSK will pay an up-front fee of $35 ...

Teva Pharmaceutical Industries' ($TEVA) Croatia-based operating unit Pliva manufactures in Eastern Europe but supplies some of Teva's drugs for the U.S. market. Among ...